

**CURRICULUM VITAE**

<b>PERSONAL INFORMATION</b>	
<i>Name</i>	<b>SARA ONALI</b>
<i>Date of birth</i>	12/02/1982
<i>Nationality</i>	ITALY
<i>E-mail</i>	SARA.ONALI@UNICA.IT
<i>Position</i>	PHD, MD ASSOCIATE PROFESSOR OF GASTROENTEROLOGY AT THE UNIVERSITY OF CAGLIARI, DEP. OF MEDICAL SCIENCE AND PUBLIC HEALTH.
<b>PROFILE</b>	
<i>Brief description</i>	<p>Research and development of new drugs for the therapy of Inflammatory Bowel Disease (IBD).  Participation as sub-investigator in the phase 1 trial (MONGERSEN in Crohn's disease)  Phase II-III IBD clinical trials since 2006 (Role sub-investigator-Study coordinator)  Natural History of Crohn's disease Recurrence  Comparative effectiveness in IBD treatment  Cooperation in IBD-clinical research in IBD with multidisciplinary approach.  Cooperation with Italian group for the study of Inflammatory bowel disease (IG-IBD)  Last GCP certificate ICH GOOD CLINICAL PRACTICE E6 (R2), The Global Helath Network, Jan the 26th 2024</p>
<b>WORK EXPERIENCE</b>	
<i>(From 2016 to2019)</i>	Research Fellow Università degli Studi di Roma "Tor Vergata
<i>(2018-2019)</i>	Medical assistant "Policlinico Tor Vergata di Roma", UOC Gastroenterologia, (prof Monteleone) Clinical trials C87088 R.S. 9/08 e SPD476/414 R.S. 57/08.
<i>(From Jan to Oct 2020)</i>	Medical assistant, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, IBD trials and research Unit .UOC di Medicina Interna e Gastroenterologia (Direttore Prof. GL Rapaccini-Prof A Gasbarrini-Prof A.Armuzzi).(Prot. N 0006491/20)
<b>EDUCATION</b>	
<i>(2000-2006)</i>	Degree in Medicine and Surgery at the University of Rome "Tor Vergata", Italy. Final mark 110/110 cum laude –Dissertation on "Recidiva della malattia di Crohn: studio prospettivo longitudinale sull'estensione ed il tipo delle lesioni prima e dopo chirurgia" (Tutor Prof F.Pallone)



	<ul style="list-style-type: none"> <li>□ Corso teorico-pratico sotto l'egida ig-ibd/sige sulla gestione delle ibd dall'immunologia alla gestione pratica e nuove prospettive, rimini febbraio 2018 . ruolo tutor-relatore. relazione:" il profiling nelle ibd"</li> <li>□ IBD master class esperti a confronto, cagliari marzo 2018, relatore:"lo screening per infezioni e vaccinazioni nelle ibd.</li> <li>□ Workshop gastro-reumatologia universo in continua espansione, messina aprile 2018, ruolo di relatore: "il rischio neoplastico e le terapie immunosoppressiva e biologica nelle ibd"</li> <li>□ Congresso nazionale FISMAD 2019, Roma Lettura patrocinata da SIGE:" Long Term Safety nella terapia Biologica nelle IBD"</li> <li>□ 7 congresso Nazionale della società italiana di gastro-reumatologia, Relazione: "Exit Strategy nelle IBD", Roma Ottobre 2019</li> <li>□ Congresso "La gestione delle IBD nell'anziano", Taormina 2019, Relazione: Caso clinico di gestione complessa.Speaker at the conference "abc..." with the presentation entitled</li> </ul>
	<i>Direction or participation in the activities of a research group at national or international level</i>
(From - to) Place	Participant for Italian Guideline for management and safety of IBD. IG-IBD
(From - to) Place	Expert opinion member for IG-IBD project for the management of pregnancy and breastfeeding in IBD
	<i>Participation in committees of scientific journals</i>
(From - to)	Revision for Journal Crohn's and Colitis, Digestive and liver disease, Inflammatory bowel disease
	<i>Teaching assignments at Phd Research Schools</i>
	NA
<b>PUBLICATIONS</b>	<p>Biancone L, Calabrese E, Petruzzello C, Onali S, Caruso A, Palmieri G, Sica GS, Pallone F . Wireless capsule endoscopy and small intestine contrast ultrasonography in recurrence of Crohn's disease. Inflamm Bowel Dis. 2007 Jun 18.</p> <p>2. Sica GS, Iaculli E, Benavoli D, Biancone L, Calabrese E, Onali S, Gaspari AL. Laparoscopic Versus Open Ileo-Colonic Resection in Crohn's Disease: Short- and Long-Term Results from a Prospective Longitudinal Study. J Gastrointest Surg. 2007 Nov 20</p> <p>3. Biancone L, Sica GS, Calabrese E, Onali S, Petruzzello C, Pallone F.Frequency and pattern of endoscopic recurrence in Crohn's disease patients with ileocolonic resection using a laparoscopic versus laparotomic approach: a prospective longitudinal study. Am J Gastroenterol. 2008 Mar;103(3):809-11.</p> <p>4. Biancone L, Onali S, Calabrese E, Petruzzello C, Zorzi F, Condino G, Sica GS, Pallone F. Non-invasive techniques for assessing postoperative recurrence in Crohn's disease. Dig Liver Dis. 2008 Jul;40 Suppl 2:S265-70.</p> <p>5. Biancone L, Calabrese E, Palmieri G, Petruzzello C, Onali S, Sica GS, Cossignani M, Condino G, Das KM, Pallone F. Ileal lesions in patients with ulcerative colitis after ileo-rectal anastomosis: relationship with</p>

- colonic metaplasia. *World J Gastroenterol.* 2008 Sep 14;14(34):5290-300.
6. Onali S, Petruzzello C, Calabrese E, Condino G, Zorzi F, Sica GS, Pallone F, Biancone L. Frequency, pattern, and risk factors of postoperative recurrence of Crohn's disease after resection different from ileo-colonic *J Gastrointest Surg.* 2009 Feb;13(2):246-52.
7. Calabrese E, Petruzzello C, Onali S, Condino G, Zorzi F, Pallone F, Biancone L. Severity of postoperative recurrence in Crohn's disease: correlation between endoscopic and sonographic findings. *Inflamm Bowel Dis.* 2009 Nov;15(11):1635-42.
8. Biancone L, Petruzzello C, Calabrese E, Zorzi F, Naccarato P, Onali S, Pallone F. Long-term safety of Infliximab for the treatment of inflammatory bowel disease: does blocking TNFalpha reduce colitis-associated colorectal carcinogenesis? *Gut.* 2009 Dec;58(12):1703.
9. Petruzzello C, Onali S, Calabrese E, Zorzi F, Ascolani M, Condino G, Lolli E, Naccarato P, Pallone F, Biancone L. Wireless capsule endoscopy and proximal small bowel lesions in Crohn's disease. *World J Gastroenterol.* 2010 Jul 14;16(26):3299-304.
10. Onali, S., Zorzi, F., Calabrese, E., Biancone, L. Steroid-free remission and closure of recto-vaginal fistula using adalimumab in a Crohn's disease patient naïve to anti-tumour necrosis factor alpha antibodies (Article) *Digestive and Liver Disease Supplements Volume 4, Issue 1, December 2010, Pages 28-30*
11. Biancone L, Petruzzello C, Orlando A, Kohn A, Ardizzone S, Daperno M, Angelucci E, Castiglione F, D'Inca R, Zorzi F, Papi C, Meucci G, Riegler G, Sica G, Rizzello F, Mocciaro F, Onali S, Calabrese E, Cottone M, Pallone F. Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study. *Inflamm Bowel Dis.* 2011 Mar;17(3):758-66.
12. Onali S, Calabrese E, Petruzzello C, Zorzi F, Sica GS, Lolli E, Ascolani M, Condino G, Pallone F, Biancone L. Endoscopic vs ultrasonographic findings related to Crohn's disease recurrence: a prospective longitudinal study at 3 years. *J Crohns Colitis.* 2010 Sep;4(3):319-28.
13. Annunziata, M.L.a, Bossa, F.b, Bozzi, R.c, Caprioli, F.d, Cassinotti, A.e, Costantino, G.f, Fiorino, G.g, Onali, S.h, Principi, M.i, Renna, S.j, Tambasco, R.k The Italian clinical experience with adalimumab in Crohn's disease: Eleven clinical cases *Digestive and Liver Disease Supplements Volume 4, Issue 1, December 2010, Pages 1-3*
14. Petruzzello C, Calabrese E, Onali S, Zuzzi S, Condino G, Ascolani M, Zorzi F, Pallone F, Biancone L. Small bowel capsule endoscopy vs conventional techniques in patients with symptoms highly compatible with Crohn's disease. *J Crohns Colitis.* 2011 Apr;5(2):139-47.
15. Monteleone G, Fantini MC, Onali S, Zorzi F, Sancesario G, Bernardini S, Calabrese E, Viti F, Monteleone I, Biancone L, Pallone F. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. *Mol Ther.* 2012 Apr;20(4):870-6.
16. Biancone L, Zuzzi S, Ranieri M, Petruzzello C, Calabrese E, Onali S, Ascolani M, Zorzi F, Condino G, Iacobelli S, Pallone F. Fistulizing pattern in Crohn's disease and pancolitis in ulcerative colitis are independent risk factors for cancer: a single-center cohort study. *J Crohns Colitis.* 2012 Jun;6(5):578-87.
17. Calabrese E, Zorzi F, Zuzzi S, Ooka S, Onali S, Petruzzello C, Lasinio GJ, Biancone L, Rossi C, Pallone F. Development of a numerical index quantitating small bowel damage as detected by ultrasonography in Crohn's disease. *J Crohns Colitis.* 2012 Sep;6(8):852-60.

18. Onali S, Calabrese E, Pallone F. Measuring disease activity in Crohn's disease. *Abdom Imaging*. 2012 Dec;37(6):927-32.
19. Ciccacci C, Biancone L, Di Fusco D, Ranieri M, Condino G, Giardina E, Onali S, Lepre T, Pallone F, Novelli G, Borgiani P. TRAF3IP2 gene is associated with cutaneous extraintestinal manifestations in Inflammatory Bowel Disease. *J Crohns Colitis*. 2012 Mar 23. [Epub ahead of print]
20. Zorzi F, Zuzzi S, Onali S, Calabrese E, Condino G, Petruzzello C, Ascolani M, Pallone F, Biancone L. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study. *Aliment Pharmacol Ther*. 2012 Jun;35(12):1397-407.
21. Zorzi F, Calabrese E, Monteleone I, Fantini M, Onali S, Biancone L, Pallone F, Monteleone G. A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease. *Aliment Pharmacol Ther*. 2012 Sep 12;36(9):850-857.
22. Onali S, Calabrese E, Petruzzello C, Zorzi F, Sica G, Fiori R, Ascolani M, Lolli E, Condino G, Palmieri G, Simonetti G, Pallone F, Biancone L. Small intestine contrast ultrasonography vs computed tomography enteroclysis for assessing ileal Crohn's disease. *World J Gastroenterol*. 2012 Nov 14;18(42):6088-95.
23. Condino G, Calabrese E, Zorzi F, Onali S, Lolli E, De Biasio F, Ascolani M, Pallone F, Biancone L. Anti-TNF-alpha treatments and obstructive symptoms in Crohn's Disease: A prospective study. *Dig Liver Dis*. 2012 Nov 26.
24. Biancone L, Calabrese E, Petruzzello C, Capanna A, Zorzi F, Onali S, Condino G, Lolli E, Ciccacci C, Borgiani P, Pallone F. A family study of asymptomatic small bowel Crohn's disease. *Dig Liver Dis*. 2013 Dec 17.
25. Italian Group for the Study of Inflammatory Bowel Disease, Armuzzi A, Biancone L, Daperno M, Coli A, Pugliese D, Annese V, Aratari A, Ardizzone S, Balestrieri P, Bossa F, Cappello M, Castiglione F, Cicala M, Danese S, D'Inca R, Dulbecco P, Feliciangeli G, Fries W, Genise S, Gionchetti P, Gozzi S, Kohn A, Lorenzetti R, Milla M, Onali S, Orlando A, Papparella LG, Renna S, Ricci C, Rizzello F, Sostegni R, Guidi L, Papi C. Adalimumab in active ulcerative colitis: a "real-life" observational study. *Dig Liver Dis*. 2013 Sep;45(9):738-43.
26. Calabrese E, Zorzi F, Onali S, Stasi E, Fiori R, Prencipe S, Bella A, Petruzzello C, Condino G, Lolli E, Simonetti G, Biancone L, Pallone F. Accuracy of small-intestine contrast ultrasonography, compared with computed tomography enteroclysis, in characterizing lesions in patients with Crohn's disease. *Clin Gastroenterol Hepatol*. 2013 Aug;11(8):950-5.
27. Monterubbianesi R, Aratari A, Armuzzi A, Daperno M, Biancone L, Cappello M, Annese V, Riegler G, Orlando A, Viscido A, Meucci G, Gasbarrini A, Guidi L, Lavagna A, Sostegni R, Onali S, Papi C, Kohn A; On behalf of the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy. *J Crohns Colitis*. 2014 Jan 25
28. Orlando A, Mocciano F, Renna S, Scimeca D, Rispo A, Lia Scribano M, Testa A, Aratari A, Bossa F, Tambasco R, Angelucci E, Onali S, Cappello M, Fries W, D'Inca R, Martinato M, Castiglione F, Papi C, Annese V, Gionchetti P, Rizzello F, Vernia P, Biancone L, Kohn A, Cottone M. Early post-operative endoscopic recurrence in Crohn's disease patients: data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort. *J Crohns Colitis*. 2014 Oct;8(10):1217-21. doi: 10.1016/j.crohns.2014.02.010. Epub 2014 Mar 11

29. Ascolani M, Mescoli C, Palmieri G, Sica G, Calabrese E, Petruzziello C, Onali S, Albertoni L, Lolli E, Condino G, Pallone F, Rugge M, Biancone L. Colonic phenotype of the ileum in Crohn's disease: a prospective study before and after ileocolonic resection. *Inflamm Bowel Dis.* 2014 Sep;20(9):1555-61. doi: 10.1097/MIB.000000000000127.
30. Lolli E, Saraceno R, Calabrese E, Ascolani M, Scarozza P, Chiricozzi A, Onali S, Petruzziello C, Chimenti S, Pallone F, Biancone L. Psoriasis Phenotype in Inflammatory Bowel Disease: A Case-Control Prospective Study. *J Crohns Colitis.* 2015 Sep;9(9):699-707. doi: 10.1093/ecco-jcc/jjv068. Epub 2015 Apr 23.
31. Monteleone G, Neurath MF, Ardizzone S, Di Sabatino A, Fantini MC, Castiglione F, Scribano ML, Armuzzi A, Caprioli F, Sturniolo GC, Rogai F, Vecchi M, Atreya R, Bossa F, Onali S, Fichera M, Corazza GR, Biancone L, Savarino V, Pica R, Orlando A, Pallone F. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. *N Engl J Med.* 2015 Mar 19;372(12):1104-13. doi: 10.1056/NEJMoa1407250.
32. Biancone L, Onali S, Petruzziello C, Calabrese E, Pallone F. Cancer and immunomodulators in inflammatory bowel diseases. *Inflamm Bowel Dis.* 2015 Mar;21(3):674-98. doi: 10.1097/MIB.000000000000243. Review.
33. Conigliaro P, Chimenti MS, Ascolani M, Triggianese P, Novelli L, Onali S, Lolli E, Calabrese E, Petruzziello C, Pallone F, Perricone R, Biancone L. Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients. *Autoimmun Rev.* 2016 Feb;15(2):184-90. doi: 10.1016/j.autrev.2015.11.002. Epub 2015 Nov 7. Review.
34. Onali S, Calabrese E, Petruzziello C, Lolli E, Ascolani M, Ruffa A, Sica G, Rossi A, Chiamonte C, Pallone F, Biancone L. Post-operative recurrence of Crohn's disease: A prospective study at 5 years. *Dig Liver Dis.* 2016 Jan 29. pii: S1590-8658(16)00004-9. doi: 10.1016/j.dld.2016.01.009
35. Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D'Incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). *Dig Liver Dis.* 2017 Apr;49(4):338-358. doi: 10.1016/j.dld.2017.01.141. Epub 2017 Jan 17.
36. Favale A, Onali S, Caprioli F, Pugliese D, Armuzzi A, Macaluso FS, Orlando A, Viola A, Fries W, Rispo A, Castiglione F, Mocci G, Chicco F, Usai P, Calabrese E, Biancone L, Monteleone G, Fantini MC; Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab. *Inflamm Bowel Dis.* 2019 Apr 1. pii: izz057. doi: 10.1093/ibd/izz057.
37. Di Giovangiulio M, Rizzo A, Franzè E, Caprioli F, Facciotti F, Onali S, Favale A, Stoffi C, Fehling HJ, Monteleone G, Fantini MC. Tbet Expression in Regulatory T Cells Is Required to Initiate Th1-Mediated Colitis. *Front Immunol.* 2019 Sep 11;10:2158. doi: 10.3389/fimmu.2019.02158
38. Chimenti MS, Conigliaro P, Triggianese P, Canofari C, Cedola F, Onali S, Calabrese E, Romeo S, Neri B, De Cristofaro E, Biancone L, Perricone R. Use of synthetic and biological DMARDs in patients with enteropathic spondyloarthritis: a combined gastro-rheumatological

- approach. *Clin Exp Rheumatol*. 2019 Sep-Oct;37(5):723-730. Epub 2019 Jun 6
39. Onali S, Favale A, Fantini MC. The Resolution of Intestinal Inflammation: The Peace-Keeper's Perspective. *Cells*. 2019 Apr 11;8(4). pii: E344. doi: 10.3390/cells8040344. Review
40. Zorzi F, Ghosh S, Chiaramonte C, Lolli E, Ventura M, Onali S, De Cristofaro E, Fantini MC, Biancone L, Monteleone G, Calabrese E. Response assessed by Ultrasonography as Target of Biological Treatment for Crohn's disease: Treat to target in CD using Ultrasonography. *Clin Gastroenterol Hepatol*. 2019 Dec 19.
41. Di Fusco D, Marafini I, Stolfi C, Troncone E, Onali S, Lolli E, Caprioli F, Mazza S, Raffaella C, Manzo L, Borgiani P, Giuffrida P, Di Sabatino A, Monteleone I, Monteleone G A Novel Smad7 Genetic Variant Mapping on the Genomic Region Targeted by Mongersen Is Associated with Crohn's Disease. *Biomedicines*. 2020 Jul 22;8(8):E234. doi: 10.3390/biomedicines8080234. PMID: 32707955 Free article.
- 42 Privitera G, Onali S, Pugliese D, Renna S, Savarino E, Viola A, Ribaldone DG, Buda A, Bezzio C, Fiorino G, Fantini MC, Scaldaferri F, Guidi L, Danese S, Gasbarrini A, Orlando A, Armuzzi A. Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease.. *J Crohns Colitis*. 2020 Jul 17:jjaa149. doi: 10.1093/ecco-jcc/jjaa149. Online ahead of print. PMID: 32674156
43. Scaldaferri F, Pugliese D, Privitera G, Onali S, Lopetuso LR, Rizzatti G, Settanni CR, Pizzoferrato M, Schiavoni E, Turchini L, Amatucci V, Napolitano D, Bernabei T, Mora V, Laterza L, Papa A, Guidi L, Rapaccini GL, Gasbarrini A, Armuzzi A. Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre. *United European Gastroenterol J*. 2020 Aug;8(7):775-781. doi: 10.1177/2050640620929133. Epub 2020 May 21.
44. Orlando A, Mocciaro F, Ventimiglia M, Renna S, Rispo A, Scribano ML, Testa A, Aratari A, Bossa F, Angelucci E, Onali S, Cappello M, Giunta M, Scimeca D, Macaluso FS, Castiglione F, Papi C, Annesse V, Biancone L, Kohn A, Di Mitri R, Cottone M Azathioprine for prevention of clinical recurrence in Crohn's disease patients with severe endoscopic recurrence: an IG-IBD randomized double-blind trial .*Eur Rev Med Pharmacol Sci*. 2020 Nov;24(21):11356-11364. doi: 10.26355/eurev\_202011\_23627.
45. Fantini MC, Favale A, Onali S Facciotti Tumor Infiltrating Regulatory T Cells in Sporadic and Colitis-Associated Colorectal Cancer: The Red Little Riding Hood and the Wolf. *F. Int J Mol Sci*. 2020 Sep 14;21(18):6744. doi:10.3390/ijms21186744.
46. Pugliese D, Guidi L, Privitera G, Bertani L, Tolusso B, Papparella LG, Maltinti S, Di Mario C, Onali S, Ceccarelli L, Rapaccini GL, Scaldaferri F, Gremese E, Gasbarrini A, Costa F, Armuzzi A. Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness, safety and immunogenicity in a large cohort of IBD patients. *Expert Opin Biol Ther*. 2020
- 47 Pinto S, Loddo E, Paba S, Favale A, Chicco F, Onali S, Usai P, Fantini MC Crohn's disease and ulcerative colitis patient-reported outcomes signs and symptoms for the remote management of inflammatory bowel disease during the COVID-19 pandemic. *J Patient Rep Outcomes*. 2021 Jun 24;5(1):48. doi: 10.1186/s41687-021-00323-z. PMID: 34165646 Free PMC article.
- 48 Italian Group for the Study of Inflammatory Bowel Disease Working Group:, Armuzzi A, Bortoli A, Castiglione F, Contaldo A, Daperno M,



- D'Incà R, Labarile N, Mazzuoli S, Onali S, Milla M, Orlando A, Principi M, Pugliese D, Renna S, Rizzello F, Scribano ML, Todeschini A.  
Female reproductive health and inflammatory bowel disease: A practice-based review. *Dig Liver Dis.* 2022 Jan;54(1):19-29. doi: 10.1016/j.dld.2021.05.020. Epub 2021 Jun 11. PMID: 34120858
49. Privitera G, Pugliese D, Onali S, Petito V, Scaldaferri F, Gasbarrini A, Danese S, Armuzzi A. Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy. *Autoimmun Rev.* 2021 Jun;20(6):102832. doi: 10.1016/j.autrev.2021.102832. Epub 2021 Apr 15. PMID: 33866066  
Review.
50. Marafini I, Stolfi C, Troncone E, Lolli E, Onali S, Paoluzi OA, Fantini MC, Biancone L, Calabrese E, Di Grazia A, Monteleone I, Lenti MV, Di Sabatino A, Monteleone G. A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn's Disease: A Phase II, Open-Label Study. *BioDrugs.* 2021 May;35(3):325-336. doi: 10.1007/s40259-021-00482-x. Epub 2021 Apr 51.
51. Fantini MC, Onali S, Gasbarrini A, Lopetuso LR. Immune system and gut microbiota senescence in elderly IBD patients. *Minerva Gastroenterol (Torino).* 2021 Jul 19. doi: 10.23736/S2724-5985.21.02934-X. Online ahead of print. PMID: 34278753
52. Pugliese D, Privitera G, Schepis T, Larosa L, Onali S, Scaldaferri F, Gasbarrini A, Caprioli F, Armuzzi A Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease. *Clin Gastroenterol Hepatol.* 2021 Aug 31:S1542-3565(21)00921-6. doi: 10.1016/j.cgh.2021.08.041. Online ahead of print. PMID: 34478878
53. Bezzio C, Armuzzi A, Furfaro F, Ardizzone S, Milla M, Carparelli S, Orlando A, Caprioli FA, Castiglione F, Viganò C, Ribaldone DG, Zingone F, Monterubbianesi R, Imperatore N, Festa S, Daperno M, Scucchi L, Ferronato A, Pastorelli L, Balestrieri P, Ricci C, Cappello M, Felice C, Fiorino G, Saibeni S; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study. *Aliment Pharmacol Ther.* 2021 Dec;54(11-12):1432-1441. doi: 10.1111/apt.16663. Epub 2021 Oct 25. PMID: 34694009
54. Macaluso FS, Orlando A, Papi C, Festa S, Pugliese D, Bonovas S, Pansieri C, Piovani D, Fiorino G, Fantini MC, Caprioli F, Daperno M, Armuzzi A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD); Working panel; Review panel. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. *Dig Liver Dis.* 2022 Apr;54(4):440-451. doi: 10.1016/j.dld.2022.01.127. Epub 2022 Feb 17.
55. **Onali S** 1, Pugliese D 2, Caprioli Fa 3, Orlando A 4, Biancone L 5, Nardone Om 6, Imperatore N 7, Fiorino G 8, Cappello M 9, Viola A 10, Principi Mb 11, Bezzio C 12, Aratari A 13, Carparelli S 14, Mazzuoli S 15, Manguso F 7, Grossi L 16, Bodini G 17, Ribaldone D 18, Mocci G 19, Miranda A 20, Minerba L 1, Favale A 1, Grova M 4, Scucchi L 5, Segato S 20, Fries W 10, Castiglione F 6, Armuzzi A 2, Fantini Mc 1, IG-IBD. Objective comparison of vedolizumab and ustekinumab effectiveness in Crohn's disease patients failure to TNF-alpha inhibitors. *Am J Gastroenterol.* 2022 Apr 13. doi: 10.14309/ajg.0000000000001773. Online ahead of print.

56. Pugliese D, Privitera G, Crispino F, Mezzina N, Castiglione F, Fiorino G, Laterza L, Viola A, Bertani L, Caprioli F, Cappello M, Barberio B, Ricci C, Balestrieri P, Daperno M, Pluchino D, Rizzello F, Scribano ML, Sablich R, Pastorelli L, Manguso F, Variola A, Di Sario A, Grossi L, Armuzzi A; IG-IBD LIVE Study Group. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study. *Aliment Pharmacol Ther.* 2022 Jul;56(1):95-109. doi: 10.1111/apt.16923. Epub 2022 May 12. PMID: 35876062
57. Bezzio C, Fiorino G, Ribaldone DG, Armuzzi A, Saibeni S; IG-IBD COVID-19 Study Group. IBD Flare in the COVID-19 Pandemic: Therapy Discontinuation Is to Blame. *Inflamm Bowel Dis.* 2022 Aug 16;izac173. doi: 10.1093/ibd/izac173. Online ahead of print. PMID: 35972338
58. Pugliese D, Onali S, Privitera G, Armuzzi A, Papi C. Comparative Effectiveness Research: A Roadmap to Sail the Seas of IBD Therapies. *J Clin Med.* 2022 Nov 13;11(22):6717. doi: 10.3390/jcm11226717. PMID: 36431194
59. Di Petrillo A, Kumar A, Onali S, Favale A, Fantini MC. GPR120/FFAR4: A Potential New Therapeutic Target for Inflammatory Bowel Disease. *Inflamm Bowel Dis.* 2023 Aug 5;izad161. doi: 10.1093/ibd/izad161. Online ahead of print. PMID: 37542525
60. Macaluso FS, Papi C, Orlando A, Festa S, Pugliese D, Bonovas S, Pansieri C, Piovani D, Fiorino G, Fantini MC, Caprioli F, Daperno M, Armuzzi A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD); Working panel; Review panel. Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology. *Dig Liver Dis.* 2023 Apr;55(4):442-453. doi: 10.1016/j.dld.2023.01.155. Epub 2023 Feb 13. PMID: 36792429
61. Fantini MC, Loddo E, Petrillo AD, Onali S. Telemedicine in inflammatory bowel disease from its origin to the post pandemic golden age: A narrative review. *Dig Liver Dis.* 2023 Jun 15;S1590-8658(23)00667-9. doi: 10.1016/j.dld.2023.05.035. Online ahead of print. PMID: 37330279
62. Dragoni G, Castiglione F, Bezzio C, Pugliese D, Spagnuolo R, Viola A, Cocomazzi F, Aratari A, Savarino EV, Balestrieri P, Onali S, Viganò C, Ribaldone DG, Innocenti T, Testa A, Saibeni S, Privitera G, Milla M, Armuzzi A, Fantini MC, Fiorino G. Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG-IBD study. *United European Gastroenterol J.* 2023 Apr;11(3):271-281. doi: 10.1002/ueg2.12367. Epub 2023 Mar 21. PMID: 36942657 Free PMC article.
62. Carpineti C, Mugheddu C, Cadoni M, Anedda J, Atzori L, Fantini MC, Onali S. Multiple Orocutaneous Extraintestinal Manifestations in Ulcerative Colitis Patient: Complete Response to Ustekinumab. *Inflamm Bowel Dis.* 2023 Sep 1;29(9):1512-1514. doi: 10.1093/ibd/izad107.
64. Bezzio, C., Venero, M., Costa, S., ...Gottin, M., Conforti, F.S. SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves. *BMC Gastroenterology*, 2023, 23(1), 230
65. Fantini MC, Fiorino G, Colli A, Laharie D, Armuzzi A, Caprioli FA, Gisbert JP, Kirchgesner J, Macaluso FS, Magro F, Ghosh S; PRACTICE-IBD study group. doi: 10.1093/ecco-jcc/jjae026. Online ahead of print Pragmatic trial design to compare real-world effectiveness of different treatments for inflammatory bowel diseases: the PRACTICE-IBD European consensus. *J Crohns Colitis.* 2024 Feb 17;jjae026.
66. Nardone OM, Bruzzese D, Allocca M, Calabrese G, Caprioli F, Danese S, Fantini MC, Onali S, Orlando A, Rispo A, Savarino E, Soriano A, Testa A, Variola A, Castiglione F; IBD-Disk Italian Study Group. Italian validation of the IBD-disk tool for the assessment of disability in inflammatory bowel diseases: A cross-sectional multicenter study. *Dig Liver Dis.* 2024 Nov 30;S1590-8658(24)01094-6. doi: 10.1016/j.dld.2024.11.004. Online ahead of print. PMID: 39617658
67. Cadoni M, Favale A, Piras R, Demurtas M, Soddu P, Usai A, Ibba I, Fantini MC, **Onali S.** Adherence to Mediterranean Diet and Diet Quality in Patients with Inflammatory Bowel Disease: A Single-Center, Observational, Case-Control Study. *Nutrients.* 2024 May 21;16(11):1557. doi: 10.3390/nu16111557. PMID: 38892491
68. **Calabrese E, Onali S,** Variola A, Ribaldone DG, Savarino EV, Viola A, Saibeni S, Conforti FS, Testa A, Latella G, Orlando A, Principi M, Privitera AC, Guerra M, Ceccarelli L, Mocchi G, Boy D, Piccarozzi MA, Gualberti G, Marando F, Gemignani L, D'Amico F. Suboptimal disease control and contributing factors in

Italian IBD patients: The IBD-PODCAST Study. *Dig Liver Dis.* 2025 Jan;57(1):241-250. doi: 10.1016/j.dld.2024.08.040. Epub 2024 Sep 19. PMID: 39299813

69. Nicola Lutz, Agnese Favale, Mauro Demurtas, Stefano Del Giacco, Sara Onali and Massimo Claudio Fantini. Eosinophilic esophagitis in the “atopic march”: dupilumab as an “umbrella” strategy for multiple coexisting atopic diseases *Front. Med.*, 21 January 2025 Sec. Gastroenterology Volume 11 - 2024 | <https://doi.org/10.3389/fmed.2024.1513417>

70. Fiorino G, Caprioli FA, Onali S, Macaluso FS, Bezzio C, Armelao F, Armuzzi A, Baldoni M, Bodini G, Castiglione F, Daperno M, Festa S, Furfaro F, Gionchetti P, Leone S, Luglio G, Milla M, Mocchi G, Napolitano D, Orlando A, Previtali E, Pugliese D, Renna S, Rispo A, Saibeni S, Sampietro G, Savarino E, Scaldaferrì F, Spagnuolo R, Variola A, Viola A, Viscido A, Vitale G, Zaetta D, Zingone F, Colli A, Fantini MC. Adaptation of the European Crohn's Colitis Organisation quality of care standards to Italy: The Italian Group for the study of inflammatory bowel disease consensus.

*Dig Liver Dis.* 2025 Apr 5:S1590-8658(25)00288-9. doi: 10.1016/j.dld.2025.03.010. Online ahead of print. PMID: 40189424 Review.